Skip to content

Arcus Biosciences RCUS Investments - Amortized Cost Basis

Investments - Amortized Cost Basis at other companies

Merck & Co. logo
Merck & Co.MRK
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
AbbVie logo
AbbVieABBV
Exelixis logo
ExelixisEXEL
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.54B+226%
Enterprise value$3.46B+275%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's investments - amortized cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's investments - amortized cost basis?
Arcus Biosciences (RCUS) reported investments - amortized cost basis of $877M in Q1 2026.
How has Arcus Biosciences's investments - amortized cost basis changed year-over-year?
Arcus Biosciences's investments - amortized cost basis decreased by 12.7% year-over-year, from $1.01B to $877M.
What is the long-term trend for Arcus Biosciences's investments - amortized cost basis?
Over 3 years (2022 to 2025), Arcus Biosciences's investments - amortized cost basis has grown at a -4.1% compound annual growth rate (CAGR), from $1.15B to $1.01B.